Biogen Inc. (BIIB) News Headlines

▮ More

Date

Headline

1/29/2023 7:53:21 PM Eisai : Lecanemab Receives Priority Review Status In Japan For Alzheimer's Disease Treatment

1/26/2023 7:23:36 PM Eisai : EMA Accepts MAA For Lecanemab As Treatment For Early Alzheimer's Disease

1/10/2023 7:32:56 PM Eisai Submits MAA For Lecanemab As Treatment For Early Alzheimer's Disease In Europe

1/6/2023 11:52:28 PM Eisai Submits SBLA To FDA For Traditional Approval Of Leqembi For Alzheimer's Disease Treatment

1/6/2023 11:31:17 PM FDA Approves Eisai And Biogen's Leqembi For Alzheimer's Disease Treatment

1/5/2023 8:04:46 AM Biogen Names Priya Singhal As EVP, Head Of Development

1/4/2023 8:03:47 AM Biogen Announces License Agreement With Alcyone For ThecaFlex DRx System

1/4/2023 7:41:52 AM Biogen, Alcyone Therapeutics Enter License Agreement To Develop Alcyone's ThecaFlex DRx System

12/30/2022 4:25:21 PM Congress Report Says FDA Broke Protocols In Approval Of Biogen Alzheimer's Drug

12/19/2022 8:16:08 AM Biogen Signs Agreement With Genentech For Royalties On Glofitamab

12/19/2022 7:48:27 AM Biogen Agrees With Genentech To Get Royalties On Commercialization For Glofitamab

12/9/2022 7:45:01 AM Biogen : FDA Accepts BLA For BIIB800, Biosimilar Candidate Referencing ACTEMRA

12/9/2022 7:36:27 AM Biogen Says FDA Accepts For Review The Abbreviated BLA For BIIB800

12/5/2022 8:01:22 AM Biogen's Tofersen MAA Accepted In Europe To Treat Rare, Genetic Form Of ALS

12/5/2022 7:38:02 AM Biogen: EMA Accepts Tofersen Marketing Authorization Application To Treat Rare, Genetic Form Of ALS

11/29/2022 9:18:18 PM Eisai Clarifies Lecanemab Not Associated With Two Deaths In Alzheimer's Disease Treatment Trial

11/29/2022 7:54:39 PM Eisai Presents Full Results Of Lecanemab Phase 3 Confirmatory Clarity Ad Study For Early Alzheimer's Disease

11/29/2022 3:15:31 PM Eisai, Biogen Hit By 2nd Death Related To Alzheimer Trial Drug

11/14/2022 10:30:29 AM Uptrend Continues For Biogen Shares

11/10/2022 8:29:59 AM Biogen Appoints Christopher Viehbacher As President And CEO